CN110313935A - A kind of high-throughput tumor screening analysis platform of intelligence - Google Patents
A kind of high-throughput tumor screening analysis platform of intelligence Download PDFInfo
- Publication number
- CN110313935A CN110313935A CN201910585451.9A CN201910585451A CN110313935A CN 110313935 A CN110313935 A CN 110313935A CN 201910585451 A CN201910585451 A CN 201910585451A CN 110313935 A CN110313935 A CN 110313935A
- Authority
- CN
- China
- Prior art keywords
- tumor
- analysis platform
- screening
- screening analysis
- detection device
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 81
- 238000012106 screening analysis Methods 0.000 title claims abstract description 22
- 238000001514 detection method Methods 0.000 claims abstract description 34
- 238000012216 screening Methods 0.000 claims abstract description 19
- 239000008280 blood Substances 0.000 claims abstract description 14
- 210000004369 blood Anatomy 0.000 claims abstract description 14
- 238000009595 pap smear Methods 0.000 claims abstract description 13
- 238000002604 ultrasonography Methods 0.000 claims abstract description 13
- 238000012360 testing method Methods 0.000 claims abstract description 12
- 210000000988 bone and bone Anatomy 0.000 claims abstract description 11
- 238000002052 colonoscopy Methods 0.000 claims abstract description 11
- 238000007689 inspection Methods 0.000 claims description 19
- 230000003993 interaction Effects 0.000 claims description 6
- 108010072866 Prostate-Specific Antigen Proteins 0.000 claims description 3
- 210000000936 intestine Anatomy 0.000 claims description 2
- 239000000439 tumor marker Substances 0.000 claims 2
- 102100038358 Prostate-specific antigen Human genes 0.000 claims 1
- 239000012530 fluid Substances 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 abstract description 14
- 230000000694 effects Effects 0.000 abstract description 4
- 201000011510 cancer Diseases 0.000 description 10
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 9
- 230000003902 lesion Effects 0.000 description 7
- 238000001574 biopsy Methods 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- 208000009608 Papillomavirus Infections Diseases 0.000 description 2
- 102000007066 Prostate-Specific Antigen Human genes 0.000 description 2
- 238000009534 blood test Methods 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 208000019065 cervical carcinoma Diseases 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- 208000021145 human papilloma virus infection Diseases 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000012895 Gastric disease Diseases 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- 108010027814 HSP72 Heat-Shock Proteins Proteins 0.000 description 1
- 102100034051 Heat shock protein HSP 90-alpha Human genes 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 101001016865 Homo sapiens Heat shock protein HSP 90-alpha Proteins 0.000 description 1
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 208000008771 Lymphadenopathy Diseases 0.000 description 1
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 description 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 208000006990 cholangiocarcinoma Diseases 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 208000014616 embryonal neoplasm Diseases 0.000 description 1
- 208000022532 enlargement of lymph nodes Diseases 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 210000002149 gonad Anatomy 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 238000002558 medical inspection Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- ODOJGYBXTZYZCP-UHFFFAOYSA-N molybdenum palladium Chemical compound [Mo].[Pd].[Pd].[Pd] ODOJGYBXTZYZCP-UHFFFAOYSA-N 0.000 description 1
- 201000011216 nasopharynx carcinoma Diseases 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000000505 pernicious effect Effects 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 208000018556 stomach disease Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B1/00—Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopes; Illuminating arrangements therefor
- A61B1/273—Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopes; Illuminating arrangements therefor for the upper alimentary canal, e.g. oesophagoscopes, gastroscopes
- A61B1/2736—Gastroscopes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B1/00—Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopes; Illuminating arrangements therefor
- A61B1/31—Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopes; Illuminating arrangements therefor for the rectum, e.g. proctoscopes, sigmoidoscopes, colonoscopes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/0059—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence
- A61B5/0075—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence by spectroscopy, i.e. measuring spectra, e.g. Raman spectroscopy, infrared absorption spectroscopy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/14546—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring analytes not otherwise provided for, e.g. ions, cytochromes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
- A61B6/02—Arrangements for diagnosis sequentially in different planes; Stereoscopic radiation diagnosis
- A61B6/03—Computed tomography [CT]
- A61B6/032—Transmission computed tomography [CT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
- A61B6/02—Arrangements for diagnosis sequentially in different planes; Stereoscopic radiation diagnosis
- A61B6/03—Computed tomography [CT]
- A61B6/037—Emission tomography
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B8/00—Diagnosis using ultrasonic, sonic or infrasonic waves
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Pathology (AREA)
- Surgery (AREA)
- General Health & Medical Sciences (AREA)
- Medical Informatics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Optics & Photonics (AREA)
- Radiology & Medical Imaging (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- High Energy & Nuclear Physics (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Theoretical Computer Science (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Biotechnology (AREA)
- Hospice & Palliative Care (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Gastroenterology & Hepatology (AREA)
- Measuring And Recording Apparatus For Diagnosis (AREA)
- Ultra Sonic Daignosis Equipment (AREA)
Abstract
The invention discloses a kind of high-throughput tumor screening analysis platforms of intelligence, including blood testing device, B ultrasound detection device, PET-CT diagnostic equipment, gynaecology's physical examination Pap smear detector, gastroscope device, colonoscopy device, tumor markers screening detection device, bone scanning device, noctovisor scan instrument；Blood testing device, B ultrasound detection device, PET-CT diagnostic equipment, gynaecology's physical examination Pap smear detector, gastroscope device, colonoscopy device, tumor markers screening detection device, bone scanning device and the noctovisor scan instrument passes through signal line and connect with COMPUTER DETECTION analytical unit.By adopting the above technical scheme, tumor examination quickly, comprehensively and accurately can be obtained as a result, improving screening efficiency in tumour early stage, strive for the discovery as early as possible of tumour, it is ensured that tumour early stage is effectively treated, and improves effects of clinic diagnosis, mitigates the pain of patient and family members.
Description
Technical field
The invention belongs to the technical fields of medical inspection.More particularly it relates to a kind of high-throughput tumour sieve of intelligence
Look into analysis platform.
Background technique
Tumour, special malignant tumour are more serious diseases, bring greatly pain and economy negative to patient and family members
Load.All there are no very effective treatment methods at present for number of types of malignant tumour.Tumour is divided into benign pernicious,
Check the tumour of itself, there are many methods at present, and tumor screening is the important channel of early detection cancer and precancerous lesion.Body
Every blood test index, B ultrasound, X-ray, anal orifice and rectal intestine refer to inspection in inspection, and the Pap smear, mammary gland molybdenum palladium in gynaecology's physical examination take the photograph piece
Deng the method for being all common screening tumour.
But these test modes be all it is independent, early detections can only be carried out for a certain or several tumours.It arrives
So far, there are no a kind of powerful, excellent effect, the comprehensive infantile tumour inspection method of type and its corresponding systems
System.
Summary of the invention
The present invention provides a kind of high-throughput tumor screening analysis platform of intelligence, the purpose is to realize tumour early stage quickly,
Comprehensively obtain accurate tumor examination result.
To achieve the goals above, the technical scheme adopted by the invention is as follows:
The high-throughput tumor screening analysis platform of intelligence of the invention, including blood testing device, B type ultrasound examination dress
It sets, PET-CT diagnostic equipment, gynaecology's physical examination Pap smear detector, gastroscope device, colonoscopy device, tumor markers screening detection
Device, bone scanning device, noctovisor scan instrument；The blood testing device, B ultrasound detection device, PET-CT diagnosis
Instrument, gynaecology's physical examination Pap smear detector, gastroscope device, colonoscopy device, tumor markers screening detection device, bone scanning dress
It sets and noctovisor scan instrument passes through signal line and connect with COMPUTER DETECTION analytical unit.
The COMPUTER DETECTION analytical unit carries out data processing and analysis to the signal that above-mentioned apparatus acquires.
The tumor screening analysis platform is equipped with human-computer interaction module, and the human-computer interaction module is equipped with display dress
It sets and input unit；The display device and input unit carries out signal connection with COMPUTER DETECTION analytical unit.
The tumor markers include S-CEA CEA, AFP AFP, prostate-specific-antigen PSA, suede
Chorionic Gonadotropin HCG,
The tumor screening analysis platform includes blood testing device, B ultrasound detection device, PET-CT diagnosis
Instrument, gynaecology's physical examination Pap smear detector, gastroscope device, colonoscopy device, tumor markers screening detection device, bone scanning dress
Set, noctovisor scan instrument and COMPUTER DETECTION analytical unit are installed on the body of the tumor screening analysis platform,
And fastened on body by connection structure, which is dismountable connection structure.
The present invention by adopting the above technical scheme, can obtain tumor examination quickly, comprehensively and accurately in tumour early stage
As a result, improving screening efficiency, strive for the discovery as early as possible of tumour, it is ensured that tumour early stage is effectively treated, and improves effects of clinic diagnosis,
Mitigate the pain of patient and family members.
Specific embodiment
Below by the description to embodiment, specific embodiments of the present invention will be described in further detail, with side
Those skilled in the art is helped to have more complete, accurate and deep understanding to inventive concept of the invention, technical solution.
The present invention is a kind of high-throughput tumor screening analysis platform of intelligence.
In order to solve the problems, such as of the existing technology and overcome its defect, realizes and quickly, comprehensively obtained in tumour early stage
The goal of the invention of accurate tumor examination result, the technical scheme adopted by the invention is as follows:
The high-throughput tumor screening analysis platform of intelligence of the invention, including blood testing device, B type ultrasound examination dress
It sets, PET-CT diagnostic equipment, gynaecology's physical examination Pap smear detector, gastroscope device, colonoscopy device, tumor markers screening detection
Device, bone scanning device, noctovisor scan instrument；The blood testing device, B ultrasound detection device, PET-CT diagnosis
Instrument, gynaecology's physical examination Pap smear detector, gastroscope device, colonoscopy device, tumor markers screening detection device, bone scanning dress
It sets and noctovisor scan instrument passes through signal line and connect with COMPUTER DETECTION analytical unit.
By adopting the above technical scheme, can tumour early stage quickly, comprehensively and accurately obtain tumor examination as a result,
Screening efficiency is improved, strives for the discovery as early as possible of tumour, it is ensured that tumour early stage is effectively treated, and improves effects of clinic diagnosis, mitigates and suffers from
The pain of person and family members.
Blood test is that the important means of early-stage cancer is found in physical examination, detects various tumor markers indexs in blood
Whether increase, then can find, identify various malignant tumours.
Pap smear in gynaecology's physical examination: using the method for pap staining, early cervical carcinoma, recall rate about 60% be can detect
~70%.Using color Doppler imaging, it can clearly find whether the most of organs of whole body have lump and lesion.Stomach
Mirror and colonoscopy: the stomach that directly detects by an unaided eye, the color of intestinal mucosa, vascular lake, gland mouth form, to identify whether there is or not lesion,
Biopsy can be done to suspicious lesions to make a definite diagnosis.PET-CT combines PET and CT perfection together, provides the detailed function of lesion by PET
With the molecular informations such as metabolism, and CT provides the precise anatomical positioning of lesion, and primary image can get whole body tomograph in all directions
Picture has the characteristics that sensitive, accurate, special and registration, can open-and-shut understanding whole body integral status, reach early stage
It was found that lesion and the purpose to diagnose the illness.
The COMPUTER DETECTION analytical unit carries out data processing and analysis to the signal that above-mentioned apparatus acquires.
The tumor screening analysis platform is equipped with human-computer interaction module, and the human-computer interaction module is equipped with display dress
It sets and input unit；The display device and input unit carries out signal connection with COMPUTER DETECTION analytical unit.
The tumor markers include S-CEA CEA, AFP AFP, prostate-specific-antigen PSA, suede
Chorionic Gonadotropin HCG.
Tumor markers screening:
Such as: the inspection mono- hydroxyl phenol substance of An Shuding is that one kind, single the higher of hydroxyl phenol meet tumor screening in tumor markers
Parameter, tumor markers screening typically belongs to wide spectrum means, and body concrete condition and symptom need to be cooperated to carry out, had certain
It is probability.
For another example: AFP AFP can look into primary hepatoma, gonad embryonal tumors.Carcinoembryonic Antigen CEA is obvious
It is common to have colon cancer, gastric cancer, lung cancer, cholangiocarcinoma when raising；There are also have liter when liver cancer, breast cancer, oophoroma, cancer of pancreas
It is high.
Long-term smoking or contact toxic and harmful gas history, regular chest x-ray inspection and tumor markers (CEA, SCC, NSE,
TPA) joint inspection.Middle-aged women periodically makees the inspection of infrared ray galactophore scanning and tumor markers (CEA, CAl5-3, TPA) connection
It closes and checks.Lump obviously then looks into cancer cell as breast puncture.There is chronic gastropathy history to make gastroscope and tumor markers (CEA, CA72-
4, CA19-9, CA242) joint inspection.Gastric-mucosa tissue biopsy is taken to make a definite diagnosis under Electronic Speculum.Cancer of pancreas clinic is easy mistaken diagnosis, suspected of pancreas
Gland cancer should make B ultrasound and tumor markers (CEA, CA19-9, CA125, CA50) joint inspection.Continue hematochezia person and is elected to be tumour mark
Will object (CEA, CA19-9, CA50) joint inspection.Rectal biopsy is made a definite diagnosis.It is that B is super and tumor markers suspected of oophoroma
(CEA, CA125, CAl9-9) joint inspection；Laparoscope takes ovary tissue biopsy to make a definite diagnosis.
If being in High Phc Incidence Area, or there is chronic viral hepatitis (especially hepatitis B and hepatitis), it should do B ultrasound, second
Five markers of liver and tumor markers (AFP, AFU) joint inspection.
35 years old or more women and human papilloma virus infection (HPV) are the High risk groups of cervical carcinoma, should periodically make vagina
Exfoliative cytology inspection or thin-layer cell tabletting technology inspection (TCT) and tumor markers (SCC, CAl25, TPA) joint inspection
It looks into.It is made a definite diagnosis under gynecatoptron as pathological biopsy.
It is in the district occurred frequently of nasopharyngeal carcinoma, should periodically make virus checking, makees Puncture cytology inspection and pathological biopsy when necessary
To make a definite diagnosis.Middle-aging male is susceptible to suffer from prostate cancer, needs tumor markers (PSA) joint inspection.If often there is dizziness, low-heat,
Pale complexion, anaemia, liver, spleen and enlargement of lymph nodes, bleeding or blutpunkte, do blood routine and haemocyte plate coating checking is most simple
Just practical.If prompt has Malignancy in blood picture, as long as snap shot marrow does cytolgical examination and can pay a home visit
It is disconnected.
Tumor markers Heat shock protein72 (Hsp90 α) is positively correlated with malignancy of tumor, as long as soon as inspection pumping is bled,
It whether can detecte out with cancer.
The tumor screening analysis platform includes blood testing device, B ultrasound detection device, PET-CT diagnosis
Instrument, gynaecology's physical examination Pap smear detector, gastroscope device, colonoscopy device, tumor markers screening detection device, bone scanning dress
Set, noctovisor scan instrument and COMPUTER DETECTION analytical unit are installed on the body of the tumor screening analysis platform,
And fastened on body by connection structure, which is dismountable connection structure.
The present invention is exemplarily described above, it is clear that present invention specific implementation is not subject to the restrictions described above,
As long as using the improvement for the various unsubstantialities that the inventive concept and technical scheme of the present invention carry out, or not improved by this
The conception and technical scheme of invention directly apply to other occasions, within the scope of the present invention.
Claims (5)
1. a kind of high-throughput tumor screening analysis platform of intelligence, it is characterised in that: the tumor screening analysis platform includes blood
Fluid inspection device, B ultrasound detection device, PET-CT diagnostic equipment, gynaecology's physical examination Pap smear detector, gastroscope device, intestines
Lens device, tumor markers screening detection device, bone scanning device, noctovisor scan instrument；The blood testing device, Type B
Ultrasonic detection device, PET-CT diagnostic equipment, gynaecology's physical examination Pap smear detector, gastroscope device, colonoscopy device, tumor-marker
Object screening detection device, bone scanning device and noctovisor scan instrument pass through signal line and COMPUTER DETECTION analytical unit connects
It connects.
2. the high-throughput tumor screening analysis platform of intelligence described in accordance with the claim 1, it is characterised in that: the calculating machine examination
It surveys analytical unit and data processing and analysis is carried out to the signal that above-mentioned apparatus acquires.
3. the high-throughput tumor screening analysis platform of intelligence described in accordance with the claim 1, it is characterised in that: the tumor screening
Analysis platform is equipped with human-computer interaction module, and the human-computer interaction module is equipped with display device and input unit；The display
Device and input unit carry out signal connection with COMPUTER DETECTION analytical unit.
4. the high-throughput tumor screening analysis platform of intelligence described in accordance with the claim 1, it is characterised in that: the tumor-marker
Object includes S-CEA CEA, AFP AFP, prostate-specific-antigen PSA, human chorionic gonadtropin HCG.
5. the high-throughput tumor screening analysis platform of intelligence described in accordance with the claim 1, it is characterised in that: the tumor screening
Analysis platform includes blood testing device, B ultrasound detection device, PET-CT diagnostic equipment, the detection of gynaecology's physical examination Pap smear
Instrument, gastroscope device, colonoscopy device, tumor markers screening detection device, bone scanning device, noctovisor scan instrument and computer
It tests and analyzes unit to be installed on the body of the tumor screening analysis platform, and is carried out on body by connection structure
Fastening, the connection structure are dismountable connection structure.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910585451.9A CN110313935A (en) | 2019-07-01 | 2019-07-01 | A kind of high-throughput tumor screening analysis platform of intelligence |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910585451.9A CN110313935A (en) | 2019-07-01 | 2019-07-01 | A kind of high-throughput tumor screening analysis platform of intelligence |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110313935A true CN110313935A (en) | 2019-10-11 |
Family
ID=68122161
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910585451.9A Withdrawn CN110313935A (en) | 2019-07-01 | 2019-07-01 | A kind of high-throughput tumor screening analysis platform of intelligence |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110313935A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113100697A (en) * | 2021-04-09 | 2021-07-13 | 中国人民解放军南部战区空军医院 | Multifunctional medical detection device |
-
2019
- 2019-07-01 CN CN201910585451.9A patent/CN110313935A/en not_active Withdrawn
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113100697A (en) * | 2021-04-09 | 2021-07-13 | 中国人民解放军南部战区空军医院 | Multifunctional medical detection device |
| CN113100697B (en) * | 2021-04-09 | 2024-04-16 | 合肥市健晖医学研究有限责任公司 | Multifunctional medical detection device |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Rubini et al. | Role of 18F-FDG PET/CT in diagnosing peritoneal carcinomatosis in the restaging of patient with ovarian cancer as compared to contrast enhanced CT and tumor marker Ca-125 | |
| Hocke et al. | Contrast-enhanced endoscopic ultrasound in discrimination between benign and malignant mediastinal and abdominal lymph nodes | |
| Harmsen et al. | Discriminating chronic pancreatitis from pancreatic cancer: Contrast-enhanced EUS and multidetector computed tomography in direct comparison | |
| WO2018157831A1 (en) | Lung cancer monitoring kit and application method thereof | |
| Liu et al. | Gastric sub-epithelial tumors: identification of gastrointestinal stromal tumors using CT with a practical scoring method | |
| Sun et al. | Colonography by CT, MRI and PET/CT combined with conventional colonoscopy in colorectal cancer screening and staging | |
| Tanaka et al. | Role of endoscopic ultrasound for gallbladder disease | |
| Liu et al. | Preliminary opinion on assessment categories of stomach ultrasound report and data system (Su-RADS) | |
| Tang et al. | Contrast‐enhanced harmonic endoscopic ultrasound (CH‐EUS) MASTER: A novel deep learning‐based system in pancreatic mass diagnosis | |
| CN110313935A (en) | A kind of high-throughput tumor screening analysis platform of intelligence | |
| Liu et al. | Improving the surgical effect for primary liver cancer with intraoperative fluorescence navigation compared with intraoperative ultrasound | |
| WO2016003013A1 (en) | Apparatus and method for early diagnosis of breast cancer | |
| Lequoy et al. | Sarcoidosis lung nodules in colorectal cancer follow-up: sarcoidosis or not? | |
| Dong et al. | Validity of 18F-fluorodeoxyglucose positron emission tomography/computed tomography for pretreatment evaluation of patients with cervical carcinoma: a retrospective pathology-matched study | |
| CN210192613U (en) | Mobile device of intelligent high-flux tumor screening and analyzing platform | |
| Wang et al. | Ultrasonography with the colonic segment-approach for colonic polyps in children | |
| Atici et al. | Preoperative use of PET/CT in patients with colorectal and gastric cancer and its impact on treatment decision making | |
| Lee et al. | Multiple carcinoid tumors of the small intestine preoperatively diagnosed by double-balloon endoscopy | |
| Xue et al. | Clinical value of SMI combined with low-dose CT scanning in differential diagnosis of thyroid lesions and tumor staging | |
| Liu et al. | Microendoscopy in vivo for the pathological diagnosis of cervical precancerous lesions and early cervical cancer | |
| Aich et al. | Sister Mary Joseph′ s nodule | |
| Zhou et al. | Modified Model for Diagnosing Breast Imaging Reporting and Data System Category 3 to 5 Breast Lesions: Retrospective Analysis and Nomogram Development | |
| Wang et al. | Superficial Flat-Type Early-Stage Gastric Signet Ring Cell Carcinoma in the Atrophic Background Mucosa: Two Case Reports | |
| Biswas et al. | Clinical Value of Serum Cancer Antigen 19-9 as a Tumor Screening Marker among Healthy Individuals | |
| Kamiyama et al. | Incidental detection of malignant lymphoma in subjects in a cancer surveillance programme |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20191011 |